11th Market Access, Pricing & Reimbursement 2024 Americas
Defining Value to Obtain Informed Evidence Optimizing Patient Access to Medicines
Day 2 - Thursday 31st October 2024
CHALLENGES & OPPORTUNITIES
- Advantages of market access teams in payer relationship
- Payer evidence requirement in early development
- Best practices to obtain better pricing and reimbursement
- Strategies to improve a better payer relationship
- Understanding and including the patients’ perspectives in designing clinical trials and clinical endpoint
- Key principles that ensure access to treatment based on need
- Patient-centeredness, patient advocacy
- Access to innovative medicines remains a key issue worldwide
- Limitations of the some of the initiatives to address this
- How can pharmaceutical companies and health authorities work together to bridge the gap
- How the pharmaceutical industry will need to navigate the potential access challenges in the
- US associated with the Inflation Reduction Act and Medicare having the authority to negotiate drug prices
- Summary of CMS’s proposed approach to measuring value and determining a maximum fair price
- Highlight innovative policy options that CMS should consider for robust Medicare drug price negotiations
- Lessons learned from negotiating drug prices with governments outside of the US.
Danielle Bargo, Director, Real World Evidence and HEOR, Eisai
- Why is this important?
- Current state of play
- Barriers to Equity Pricing
- Potential solutions and some principles to maximize impact of Equity Pricing
- Effective communications with internal and external stakeholders
- Importance of stakeholder collaboration
- Understanding the benefits of a good collaboration between payers and pharma to ensure appropriate patient access
- Challenges in drug pricing and reimbursement
- How to navigate a complex balance between financial and strategic risks
- Strategies to offset regulatory and inflationary pressures.
- Addressing environmental, social, and corporate governance issues
- Encouraging cross-functional or cross-company collaborations
- The increasing relevance of Emerging Markets
- EMs Embrace Technological Innovation
- Creating value through partnership
- How to Avoid the Pitfalls of Innovation in Emerging Markets
- Objective: Activating the full stakeholder ecosystem to shift conversation from price to value to get access to innovative therapies
- Why is the full stakeholder ecosystem important for gaining access in the future?
- How to Identify the stakeholder ecosystem for access success
- Step by step: Setting up a cross-functional program for access success
- Assessment of financial benefit from tendering
- Evaluating its impact on prices and market concentration
- Consideration of its operational framework
- Tendering for pharmaceuticals as a reimbursement tool
- The importance of making MA the core of the company
- Bridge between pre-launch strategy and post-launch
- International Drug Price Indicator Guide WHO
- Increasing collaboration between countries
- Frontiers in Health Care
- What will the future bring?
